Stay updated with breaking news from Christopher Van Dyck. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Update on LEQEMBI Investigational Subcutaneous Formulation
In what might be the biggest news ever in Alzheimer's research, the FDA has approved a drug that actually slows the disease in some people.
Dr David Weisman, from Pennsylvania, was an advisor to two controversial Alzheimer's drug developers while also being on an FDA committee analyzing Alzheimer's drugs.
Last week the Mail on Sunday told the story of 79-year-old Genevieve Lane from Florida who died of a brain seizure after taking Alzheimer's wonder-drug lecanemab.
Federal drug regulators on Friday approved lecanemab, sold under the brand name Leqembi, an Alzheimer’s drug that appears to slow the disease.